Graduate School of Biotechnology and College of Life Science, Kyung Hee University, Gyeonggi-do, Republic of Korea.
Division of Applied Life Science and PMBBRC, Gyeongsang National University, Jinju, Republic of Korea.
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):777-788. doi: 10.1080/21691401.2020.1748639.
Probiotic Gluconacetobacter strains are intestinal microbes with beneficial effects on human health. Recently, researchers have used these strains to biosynthesize metal and non-metal nanoparticles for treating various chronic diseases. Despite their importance in nanotechnology, gold nanoparticles (AuNPs) biosynthesized by Gluconacetobacter species have not been clearly identified for treating inflammation and inflammation-associated diseases. While ginsenoside CK has strong pharmaceutical activity, it also has strong cytotoxicity and hydrophobicity which is hurdle to make formulation. Peptide-nanoparticle hybrids are gaining increasing attention for their potential biomedical applications, including human inflammatory diseases. Herein, we developed peptide CopA3 surface conjugated and ginsenoside compound K (CK) loaded gold nanoparticles (GNP-CK-CopA3), which intracellularly synthesised by the probiotic kh-1, to target lipopolysaccharide (LPS)-activated RAW264.7 macrophages. The synthetic GNP-CK-CopA3 was characterised by various instrumental techniques. The results of our cellular uptake and MTT assays exhibited obvious drug intracellular delivery without significant cytotoxicity. In addition, pre-treatment with GNP-CK-CopA3 significantly ameliorated LPS-induced nitric oxide (NO) and reactive oxygen species (ROS) production and suppressed the mRNA and protein expression of pro-inflammatory cytokines in macrophages. Furthermore, GNP-CK-CopA3 efficiently inhibited the activation of the nuclear factor-κB (NF-κB) and mitogen-activating protein kinase (MAPK) signalling pathways. Taken together, our findings highlight the potential of using peptide-nanoparticle hybrids in the development of anti-inflammatory approaches and providing the experimental foundation for further application.
生酮醋酸杆菌属益生菌是对人类健康有益的肠道微生物。最近,研究人员利用这些菌株生物合成金属和非金属纳米粒子来治疗各种慢性疾病。尽管它们在纳米技术中很重要,但尚未明确鉴定出由生酮醋酸杆菌属合成的金纳米粒子 (AuNP) 用于治疗炎症和炎症相关疾病。虽然人参皂苷 CK 具有很强的药用活性,但它也具有很强的细胞毒性和疏水性,这是制剂的障碍。肽-纳米粒子杂化物因其在包括人类炎症性疾病在内的潜在生物医学应用中受到越来越多的关注。在这里,我们开发了由益生菌 kh-1 细胞内合成的肽 CopA3 表面共轭和人参皂苷 CK 负载的金纳米粒子 (GNP-CK-CopA3),以靶向脂多糖 (LPS) 激活的 RAW264.7 巨噬细胞。通过各种仪器技术对合成的 GNP-CK-CopA3 进行了表征。细胞摄取和 MTT 测定的结果表明,没有明显细胞毒性的情况下,药物的细胞内递送明显。此外,GNP-CK-CopA3 的预处理显着改善了 LPS 诱导的一氧化氮 (NO) 和活性氧 (ROS) 产生,并抑制了巨噬细胞中促炎细胞因子的 mRNA 和蛋白表达。此外,GNP-CK-CopA3 有效地抑制了核因子-κB (NF-κB) 和丝裂原激活的蛋白激酶 (MAPK) 信号通路的激活。总之,我们的研究结果强调了使用肽-纳米粒子杂化物开发抗炎方法的潜力,并为进一步应用提供了实验基础。